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Abstract: Introduction: 188Re is a promising radionuclide for metabolic therapy 
because of the emission of high energy beta-particles. The development of water-
soluble bone-seeking polymers such as PEI-MP (polyethyleneimine, functionalised with 
methylphosphonate-groups) that might be labeled with 188Re are recent approaches, 
with a strong potential for bone cancer treatment. The aim of this study was to 
evaluate the efficacy of 188Re-PEI-MP, as 
therapeutic agent for osteosarcoma, through in vitro and in vivo models. 
Material and Methods: Radiochemical purity of 188Re-PEI-MP was achieved using 
microchromatography. In vitro studies were performed in human osteosarcoma cell-
line (MNNG-HOS). Uptake studies were performed using the complex 188Re-PEI-MP 
and Na188ReO4 as control. Cell samples were collected during four hours, centrifuged 
to separate supernatant and pellet. Subsequently, the radioactivity of each portion 
was counted to determine percentage of uptake. In vivo studies were performed using 
four groups of Balb/c nu/nu mice: two normal groups were injected with Na188ReO4 
(n=18) and 188Re-PEI-MP (n=17) respectively; two with osteosarcoma xenotransplants 
were injected with Na188ReO4 (n=17) and 188Re-PEI-MP (n=19) respectively. When 
tumor reached the appropriate volume, Na188ReO4 and 188Re-PEI-MP were 
administered by an intravenous injection in the tail vein (22-37MBq), with the animal 
anesthetized and previously placed on the gamma camera detector. Immediately, a 
dynamic acquisition followed, with a 128x128 matrix for 10 minutes (20 frames, 30 
seconds). Static images (2 minutes) were performed with a 256x256 matrix, where 
each of the four groups was divided into two groups, of which one was imaged at 120 
minutes, and the other at 240 minutes. For biodistribution proposes, mice were 
euthanized 2 and 4 hours after injection and organ samples where weighted and 
counted in a well-counter to obtain percentage injected activity per gram of 
organ (%ID/g). 
Results: In vitro results demonstrated that the uptake was higher for 188Re-PEI-MP 
(12.2%) than for Na188ReO4 
(0.2%), remaining constant over time. Biodistribution results, with Na188ReO4, 
showed a higher uptake by the thyroid, bladder and stomach, while with 188Re-PEI-
 MP the target organ was consistently the bladder, with little uptake in bone tissue and 
tumour (tumour/muscle ratio>1). The excretion of both tracers was mainly renal with a 
small fraction of the complex through hepatobilliary system. 
Conclusions: 188Re-PEI-MP seems to be an agent for metabolic therapy of bone 
cancer. However, as the in vivo 
results suggest that the bladder could be another target organ, preliminary in vitro 
results in human bladder cancer 
cell-line (CTRL1472) showed a tumour/muscle ratio greater than 1.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Foi decidido que não será apresentada a versão integral deste 
documento. 
Para obtenção de mais informações: 
www.nucmedonline.net 
cursomedicinanuclear@gmail.com 
 
 
 
It has been decided that it would not be shown the entire version 
of this document. 
To obtain more informations: 
www.nucmedonline.net 
cursomedicinanuclear@gmail.com 
 
 
